Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
Sagimet Biosciences Inc. - Series A (SGMT)
Company Research
Source: GlobeNewswire
SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting fatty acid synthase (FASN) inhibitors will be given at the upcoming 9th Annual MASH-TAG Conference being held January 9-11, 2025 in Park City, Utah. The presentation will focus on the differentiated mechanism of action of the FASN inhibitor denifanstat and the observed anti-fibrotic effect in the Phase 2b FASCINATE-2 study in F2/F3 MASH. MASH-TAG 2025 Presentation Details: Title:FASN InhibitorsPresenter:Marie O’Farrell, Ph.D. (SVP of Research and Development, Sagimet Biosciences)Session:Session 4: The Promise of New Pharmacological Agents + PathophysiologyDate/Time:Friday, January 10, 2025 at 6:10 PM MSTLocation:The Chateaux Deer Valley, Park City, Utah About Sagimet Biosciences Sagime
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. - Series A news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market [Seeking Alpha]Seeking Alpha
- Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom CombinationGlobeNewswire
- Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination ProgramGlobeNewswire
SGMT
Earnings
- 11/13/25 - Beat
SGMT
Sec Filings
- 12/18/25 - Form SCHEDULE
- 12/18/25 - Form 8-K
- 12/17/25 - Form 8-K
- SGMT's page on the SEC website